FindTrial
Sign In

TAK228

DRUG3 trials

Sponsors

M.D. Anderson Cancer Center, Imperial College London

Conditions

Anaplastic Large Cell LymphomaCD30+ Peripheral T-cell LymphomaClassical Hodgkin LymphomaFallopian Tube CancerFallopian Tube NeoplasmsLymphomaMalignant Neoplasms Stated as Primary Lymphoid HaematopoieticOvarian Cancer

Phase 1

Phase II Study of TAK228 in Relapsed Lymphoma
TerminatedNCT02727777
M.D. Anderson Cancer CenterLymphoma
Start: 2017-03-01End: 2018-07-10Updated: 2020-03-12
Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas
WithdrawnNCT03205891
M.D. Anderson Cancer CenterAnaplastic Large Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma, Classical Hodgkin Lymphoma +1
Start: 2018-03-31End: 2021-03-31Updated: 2018-01-17

Phase 2

Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
CompletedNCT03648489
Imperial College LondonFallopian Tube Cancer, Fallopian Tube Neoplasms, Ovarian Cancer +7
Start: 2018-09-21End: 2023-11-30Updated: 2024-09-20

Related Papers

DICE: Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian cancer resistant to standard treatment-a study protocol for a randomised trial investigating a novel therapy called TAK228.
2022-04-053 citations
Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).
2022-01-055 citations